Figure 2.
Outcome based on PB blast percentage, as well as cytogenetic markers. OS probability from onset of HMA treatment according to PB blast percentage (>5% vs ≤5%) (A) and cytogenetic risk (intermediate/normal vs poor) (B).
Outcome based on PB blast percentage, as well as cytogenetic markers. OS probability from onset of HMA treatment according to PB blast percentage (>5% vs ≤5%) (A) and cytogenetic risk (intermediate/normal vs poor) (B).
